Image Credit: © Dr_Microbe – stock.adobe.com
The FDA has granted Fast Track designation to Marengo Therapeutics’ invikafusp alfa (STAR0602), a first-in-class selective dual T cell agonist being evaluated as a potential new treatment for advanced colorectal cancer with high tumor mutational burden (TMB-H).1
In a press release, Zhen Su, MD, MBA, chief executive officer of Marengo Therapeutics said, “The FDA’s Fast Track designation is an important milestone for the STAR0602 program and further positions our unique selective dual T cell agonist platform as a promising solution to address key challenges that perpetuate significant unmet needs in oncology. This recognition specifically validates the promise of STAR0602 as a novel treatment option for patients with TMB-H metastatic colorectal cancer, which is insensitive to PD-1 treatment.”
The designation is based on encouraging results from the first-in-human, open-label, multi-center Phase I STARt-001 study of invikafusp alfa in heavily pretreated cancer patients. Data from the trial reinforced the potential treatment’s anti-tumor activity and favorable safety profile.
STARt-001 is evaluating invikafusp alfa as a single agent in biomarker selected patients with advanced antigen-rich solid tumors including PD-1 refractory and rare tumors. The trial is comprised of two parts with a Phase I dose escalation followed by a Phase II dose expansion.
In the press release, Bruce Chabner, MD, clinical director emeritus for the Massachusetts General Hospital Cancer Center and professor of medicine at Harvard Medical School added, “Marengo’s selective Vβ T cell activation approach targeting specific T cell subsets enriched in Tumor-infiltrating lymphocytes to enhance anti-tumor activity is unique and highly promising. The Phase II clinical investigation of invikafusp alfa is ongoing and this novel treatment could lead to a new class of therapeutics for tumor types that are PD-1 insensitive or resistant, especially in colorectal cancer where current treatment options remain limited.”
Prior to the new year, Marengo announced it had dosed the first patient for its Phase II portion of STARt-001. This Phase II trial builds on the previously mentioned portion in which invikafusp alfa was evaluated as a monotherapy. Additonally, the Phase II portion has expanded from North America to include sites in France and Spain.2
“We are thrilled to advance invikafusp alfa into Phase II with the addition of premier European oncology centers,” Ke Liu, MD, PhD, chief development officer of Marengo Therapeutics, said in an earlier press release. “The single-agent anti-tumor activity observed in Phase I, particularly in PD-1-resistant ‘cold’ tumors like colorectal cancer, gives us confidence in our approach and fuels our hope to reach as many patients as possible. The addition of renowned European institutions expands our geographical footprint and enhances our ability to enroll more PD-1 resistant patient populations. Through our Phase II study, we aim to deepen our understanding of invikafusp alfa’s mechanism of action across diverse tumor types.”
References
1. Marengo’s First-in-Class Invikafusp Alfa (STAR0602) Receives U.S. FDA Fast Track Designation for Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancers with High Tumor Mutational Burden (TMB-H). News release. Marengo. January 8, 2025. Accessed January 8, 2025. https://www.prnewswire.com/news-releases/marengos-first-in-class-invikafusp-alfa-star0602-receives-us-fda-fast-track-designation-for-treatment-of-unresectable-locally-advanced-or-metastatic-colorectal-cancers-with-high-tumor-mutational-burden-tmb-h-302344827.html
2. Marengo Announces First Patient Dosed in Phase 2 Clinical Study for its Lead Program, Invikafusp Alfa (STAR0602) in PD-1 Resistant Tumors, Expands Study to Europe. News release. Marengo. December 20, 2024. Accessed January 8, 2025. https://www.prnewswire.com/news-releases/marengo-announces-first-patient-dosed-in-phase-2-clinical-study-for-its-lead-program-invikafusp-alfa-star0602-in-pd-1-resistant-tumors-expands-study-to-europe-302336691.html